A Comparison between the Nephrotoxic Profile of Gentamicin and Gentamicin Nanoparticles in Mice

Journal of Biochemical and Molecular Toxicology - Tập 29 Số 2 - Trang 57-62 - 2015
Akram Jamshidzadeh1,2, Reza Heidari1, Soliman Mohammadi‐Samani3, Negar Azarpira4, Asma Najbi1,2, Parisa Jahani5, Narges Abdoli6
1Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2Pharmacology and Toxicology Department, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
3Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
4Transplant Research Center, School of Medicine Shiraz University of Medical Sciences Shiraz Iran
5Pharmacology and Toxicology Department Shiraz University of Medical Sciences International Branch (Kish) Shiraz Iran
6Ministry of Health Food and Drug Organization Tehran Iran

Tóm tắt

ABSTRACT

Aminoglycoside antibiotics are widely used against Gram‐negative infections. On the other hand, nephrotoxicity is a deleterious side effect associated with aminoglycoside therapy. Gentamicin is the most nephrotoxic aminoglycoside. Because of serious health complications ensue the nephrotoxicity induced by aminoglycosides, finding new therapeutic strategies against this problem has a great clinical value. This study has attempted to compare the nephrotoxic properties of gentamicin and a new nanosized formulation of this drug in a mice model. Animals were treated with gentamicin (100 mg/kg, i.p. for eight consecutive days) and nanogentamicin (100 mg/kg, i.p. for eight consecutive days). Blood urea nitrogen (BUN), plasma creatinine levels, and histopathological changes of kidney proximal tubule were monitored. It was found that gentamicin caused severe degeneration of kidney proximal tubule cells and an increase in serum creatinine and BUN. No severe injury was observed after nanogentamicin administration. This study proved that nanosized gentamicin is less nephrotoxic.

Từ khóa


Tài liệu tham khảo

10.1128/AAC.43.5.1003

10.1111/j.1445-5994.2011.02452.x

10.1093/infdis/138.4.541

10.1093/infdis/167.1.173

Luft FC, 1975, Experimental aminoglycoside nephrotoxicity, J Lab Clin Med, 86, 213

10.1038/ki.2010.337

Wedeen RP, 1983, Transport of gentamicin in rat proximal tubule, Lab Invest, 48, 212

10.3109/08860229909085109

10.3109/08860229509036371

Sandoval R, 1998, Aminoglycoside antibiotics traffic to the Golgi complex in LLC‐PK1 cells, J Am Soc Nephrol, 9, 167, 10.1681/ASN.V92167

10.1038/ki.2010.20

10.1073/pnas.79.5.1663

Williams PD, 1986, Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides, J Pharmacol Exp Ther, 237, 919

10.1016/0041-008X(81)90414-2

10.1016/0002-9343(90)90082-O

10.7326/0003-4819-100-3-352

10.1146/annurev.pa.28.040188.001555

10.2165/00003088-197803030-00002

10.1016/j.yexmp.2008.12.004

10.1016/S0168-3659(00)00339-4

10.1016/j.addr.2008.08.002

10.2298/ABS1101157E

10.1016/S1734-1140(13)70971-X

10.1016/j.jconrel.2007.01.004

Josepovitz C, 1982, Inhibition of gentamicin uptake in rat renal cortex in vivo by aminoglycosides and organic polycations, J Pharmacol Exp Ther, 223, 314

10.1016/j.bcp.2009.09.021

10.1111/j.1440-1797.2004.00247.x

10.1016/S0014-2999(03)01948-4

10.1016/j.fct.2008.07.007

10.1681/ASN.2007090982

10.1016/j.colsurfb.2011.05.050

Azhdarzadeh M, 2012, Anti‐bacterial performance of azithromycin nanoparticles as colloidal drug delivery system against different gram‐negative and gram‐positive bacteria, Adv Pharm Bull, 2, 17

10.1038/sj.bjc.6602772

10.1073/pnas.1203129109

10.1179/joc.2001.13.5.461

10.1016/j.bioelechem.2012.03.001

10.1111/jphp.12005

10.1016/S0927-7765(99)00058-2

10.1088/1468-6996/11/1/014104

10.2174/0929867311320100004